Semaglutide Clinical Trial for Alcohol Use and Heart Health in People Living with HIV

This groundbreaking clinical trial, known as the GL1DER HIV RCT, is investigating whether a medication called semaglutide (marketed as Rybelsus®) can help people living with HIV reduce their alcohol consumption and lower cardiovascular disease risk. The study specifically focuses on adults with HIV who currently drink alcohol and may also smoke cigarettes, representing a significant step forward in addressing multiple health concerns that often coexist in this population.

Understanding the Research Focus

For people living with HIV, managing the virus with antiretroviral therapy (ART) has become increasingly effective, allowing individuals to live longer, healthier lives. However, this success has revealed new health challenges. Cardiovascular disease has emerged as a leading cause of serious illness and mortality among people with HIV, even when the virus is well-controlled. Additionally, alcohol use can complicate HIV management and increase cardiovascular risks. This trial addresses these interconnected issues by testing whether semaglutide, a medication already approved for diabetes and weight management, might offer benefits beyond its primary uses.

How the Study Works

The trial will enroll approximately 200 participants aged 18-89 who have been diagnosed with HIV-1 and receive care through the Vanderbilt Comprehensive Care Clinic. Participants must be on a stable ART regimen with good viral control and have consumed alcohol within the past 90 days. The study uses a rigorous scientific design where participants are randomly assigned to receive either semaglutide or a placebo (an inactive substance), and neither the participants nor the researchers will know who receives which treatment until the study concludes.

Primary Goals and Measurements

The main objective is to determine whether semaglutide helps reduce alcohol consumption. Researchers will measure the average number of alcoholic drinks consumed per week over 30 days at the 3-month mark using a validated method called Timeline Follow Back. Secondary goals include examining whether the medication affects cigarette smoking patterns and reduces markers of systemic inflammation, particularly interleukin-6 (IL-6), which is associated with increased cardiovascular risk. The study will also assess gut permeability, calculate Reynolds Risk Scores for cardiovascular disease prediction, and evaluate mortality risk factors.

Importance for Patient Care

This research is particularly significant because it addresses multiple health behaviors simultaneously. Many people struggle with both alcohol use and smoking, and these behaviors can significantly impact heart health. For people living with HIV, these factors combine with the inherent inflammatory state associated with the virus, creating compounded health risks. Finding a single intervention that could positively influence all these areas would represent a major advancement in comprehensive HIV care.

Safety Considerations and Eligibility

The researchers have established careful exclusion criteria to ensure participant safety. Individuals with known allergies to semaglutide, those currently taking other GLP-1 receptor agonists, people with diabetes, or those with specific thyroid conditions or gastrointestinal disorders are excluded from participation. Additional exclusions include pregnancy, breastfeeding, plans to become pregnant during the study period, cognitive inability to provide consent, language barriers, and being too ill to complete study procedures.

Broader Research Context

Research into medications that can address multiple health concerns simultaneously represents an important evolution in medical science. Rather than treating each condition in isolation, this approach acknowledges that many health issues are interconnected and may share common biological pathways. The investigation of semaglutide for alcohol reduction builds on emerging evidence that GLP-1 receptor agonists might affect reward pathways in the brain that are involved in addictive behaviors. This could open new treatment possibilities for substance use disorders beyond traditional approaches.

For people living with HIV, research that addresses the whole person—not just the virus—is crucial for improving quality of life and long-term health outcomes. As HIV management has shifted from focusing solely on viral suppression to promoting overall wellness and aging successfully with HIV, studies like this one become increasingly valuable. The collaboration between Vanderbilt University Medical Center, the National Institute on Alcohol Abuse and Alcoholism, University of Louisville, and Norton Healthcare brings together diverse expertise to address these complex health challenges comprehensively.

The six-month study duration allows researchers to observe both short-term effects and initial sustainability of any changes in alcohol consumption and inflammatory markers. The inclusion of older adults acknowledges that aging with HIV presents unique challenges that require specific research attention. By focusing on individuals with well-controlled HIV, the study can specifically examine the effects of semaglutide on alcohol use and cardiovascular risk factors independent of uncontrolled viral replication.

This research represents hope for more integrated approaches to healthcare that address multiple concerns through single, well-tolerated interventions. The outcomes could potentially influence future clinical guidelines for managing cardiovascular risk and alcohol use in people living with HIV, ultimately contributing to longer, healthier lives for this population.